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Type 2 diabetes is characterized by various degrees of insulin resistance and pancreatic b-cell dysfunction. In Europe and the USA, insulin resistance with obesity is the predominant pathological manifestation of diabetes, while impaired insulin secretion is predominant in Asia. Incretin is characterized by its release from gut following ingestion of meal and its stimulatory effect on insulin secretion. Both GLP-1 and GIP have been well-characterized using KO mice, and type 2 diabetes patients generally exhibit an impaired incretin effect. Thus, GLP-1 and GIP receptor agonists, in addition to dipeptidy1-IV (DPP-IV) inhibitors that enhance endogenous incretin activity, may be indicated therapeutically against diabetes with impaired insulin secretion, as is frequently seen in Asia. Particularly noteworthy is that the effectiveness of GLP-1 is preserved while that of GIP frequently is markedly reduced in type 2 diabetes. The possible mechanisms of the inability of GIP to stimulate insulin secretion in certain conditions will also be discussed. In addition, the results of a clinical use of incretin derivatives in Japanese will be discussed.
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The role of the b-cell in the development of type 2 diabetes has now been well established. Further, genetic studies have demonstrated that most genes associated with type 2 diabetes are linked to the b-cell. While the b-cell's importance in the pathogenesis of hyperglycemia appears to be universal across ethnic groups, the relative impact of abnormal b-cell function has been debated.
Numerous approaches have been used to assess b-cell function, with the choice frequently being based on the nature of the study. In some instances this has used intravenous methodologies, others oral testing, and in a number just a fasting sample. The effect of these differences in methodologies makes it difficult to do more than make general comparisons.
To better understand the relative importance of b-cell function in different ethnic groups, it is critical to use common tests and common assays. Such a study in Asia and globally could help better define the critical role of the b-cell in the pathogenesis of type 2 diabetes. Type 2 diabetes is a complex genetic disorder caused by the interaction between genetic and environmental factors. With the environmental changes and aging of the population, the prevalence of type 2 diabetes has increased rapidly. During the past two decades, only three diabetic genes were identified by candidate approach. Since 2007, many studies using whole genome association study(GWAS) has reported identification of new type 2 diabetes gene, bring the number of type 2 diabetes gene up rapidly. We had replicated systematically these genes in Chinese population and did some meta-analysis to assess the contribution of some genes to the genetic susceptibility of type 2 diabetes in Asian population. Through those studies , we have the impression that 1) The genetic background of type 2 diabetes between Chinese and Caucasians are very different, how do these difference determine the different risk of type 2 diabetes need to be study further, especially the genetic/ environment interactions. 2) The genetic backgrounds of type 2 diabetes among East Asian population are very similar. The differences in the risk of diabetes among East Asian population might be largely determined by differences in lifestyle and environmental factors. Worldwide we are making progress on improving metabolic control of diabetes and reducing diabetes related complications but the success is by no means uniform. Due to the devastating health and economic burdens of diabetes it is essential that we do even better with diabetes prevention and care. Continued improvement depends on determining and implementing those therapeutic principles (pharmacologic and technologic) and practices (systems of care) that have been shown to enhance the ability for patients to achieve optimal control.
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First we must determine and agree on the definition of optimal diabetes/ glycemic control. The definition of optimal glycemic control is evolving to include both the level of HbA1c and the amount of hypoglycemia. Additionally factors such as patient experience (satisfaction and quality of life) and weight gain are being considered as clinical outcome markers. Recent clinical trials have generated much discussion and debate about optimal glycemic targets. New technology like continuous glucose monitoring (CGM) is starting to clarify these glycemic targets.
Next we must establish diabetes self management training that is effective in engaging patients in working to control their own diabetes. Then algorithms or roadmaps for care (systematic approach to clinical care that guides clinical decision making) need to be established, taught and implemented. Algorithms when customized for a given population can reduce variation in practice and improve quality. We need to understand why in some countries only 2% of individuals with T1D are on insulin pumps while in others it is 40%. Is it just financial resources or other factors? In T2D what is the right medication to add when metformin is no longer working and how is it decided and implemented? The timing of the initiation of insulin in T2D varies widely and few practitioners have a systematic approach to insulin adjustment which we have learned is vital to successful use of insulin.
The International Diabetes Center and others have shown the one of the biggest factors in achieving successful outcomes is how effectively patient centered team care is implemented. Patients, educators and physicians working together with common targets are components critical to success. We are seeing that use of new technology (pens, pumps, patch pumps, sensors and electronic medical records) can enhance patient understanding of their disease, improve communications between patients and providers and help guide effective clinical therapy decisions.
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